- Home
- / Krystal Biotech
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Krystal Biotech financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$176.2
2024-10-29
Market Capitalization
$5.1 B
2024-10-29
Revenue
$389.1 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2021 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.7M | 290.5M | 389.1M | ||||||
| General and administrative expense | 402.0K | 1.6M | 6.5M | 15.1M | 40.4M | 77.7M | 98.4M | 113.7M | 146.7M |
| Operating expense total | 1.1M | 4.8M | 22.1M | 33.0M | 68.3M | 120.2M | 144.8M | 167.3M | 204.8M |
| EBIT | (1.1M) | (4.8M) | (22.1M) | (33.0M) | (68.3M) | (145.2M) | (109.7M) | 65.7M | 161.3M |
| EBIT margin, % | -216.4% | 22.6% | 41.5% | ||||||
| Interest expense | 7.0K | 1.5M | 29.7M | 28.2M | |||||
| Pre tax profit | 12.9M | 95.4M | 189.5M | ||||||
| Income tax expense | 2.0M | 6.2M | (15.4M) | ||||||
| Net Income | (1.1M) | (7.9M) | (19.1M) | (32.2M) | (69.6M) | (140.0M) | 10.9M | 89.2M | 204.8M |
| EPS | (3.1) | (5.5) | 0.4 | 3.0 | 6.8 |